PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
23412015-13	2013	CONCLUSIONS: In this exploratory analysis of combination therapy with tenofovir/emtricitabine in treatment-naive patients at week 240, vRNA suppression rates and increases in baseline CD4 counts were significantly higher in raltegravir than efavirenz recipients.	Raltegravir Potassium	224-235	vault RNA 1-1	Homo sapiens	135-139	
31192893-3	2019	Raltegravir (RAL), an integrase inhibitor, has been associated with only a single rapid phase of decay, and we speculated this may be due to higher intracellular concentration (IC) of RAL in LT. We have previously measured suboptimal ICs of antiretroviral therapy agents in LT, which were associated with slower decay of both vRNA+ cells and the follicular dendritic cell network pool.	Raltegravir Potassium	0-11	vault RNA 1-1	Homo sapiens	326-330	
21921224-5	2011	RESULTS: At week 156 counting noncompleters as failures, 212 (75.4%) of 281 versus 192 (68.1%) of 282 had vRNA levels <50 copies/mL in the raltegravir and efavirenz groups, respectively [Delta (95% CI) = 7.3% (-0.2, 14.7), noninferiority P < .001].	Raltegravir Potassium	142-153	vault RNA 1-1	Homo sapiens	106-110